Psicofarmacologia

I progressi delle neuroscienze hanno aperto nuove prospettive nel campo della psicofarmacologia, in particolare per quanto riguarda la sintesi di nuove molecole con maggiore efficacia terapeutica e minori effetti collaterali. Tuttavia, al giorno d.oggi l'uso delle sostanze psicoattive - sia per le loro proprietà di alterare l'umore in ambito ricreazionale sia per i considerevoli benefici che i farmaci psicoattivi forniscono a molti pazienti affetti da patologie di tipo psichiatrico - si sta notevolmente diffondendo. Si tratta, allora, di comprendere le caratteristiche delle sostanze psicoattive, i loro effetti fisiologici e comportamentali e i meccanismi attraverso i quali essi si verificano. Il libro si caratterizza per un approccio alla psicofarmacologia a tutto campo (dagli aspetti storici agli studi comportamentali clinici e preclinici, fino alle ultime ricerche sui recettori dei farmaci e sugli effetti dei farmaci nei topi geneticamente modificati).

"The Evidence-Based Guide to Antipsychotic Medications" is designed to provide both clinicians and residents with focused, comprehensive, and clinically relevant information regarding the use of antipsychotic medications to treat a broad range of psychiatric conditions - from mood and anxiety disorders to substance abuse, personality disorders, and schizophrenia. The volume editor is a renowned psychiatrist and author with more than 25 years of experience in both clinical and research settings diagnosing and treating patients with mood and psychotic disorders. In addition, each of the volume's 13 contributors is an expert with many years of clinical experience to draw on. The book is down-to-earth and reader-friendly and is structured for maximal utility in both coverage and format: Key Clinical Points cap each chapter, synthesizing and summarizing the knowledge you can take away, and serving both as a refresher for those using the book as a reference and as a study aid to master the material; both FDA-approved and off-label use of antipsychotic medications are addressed, reflecting the reality of clinical practice on the front lines; use of antipsychotic medications in both the pediatric and geriatric populations, a potentially controversial subject, is addressed in a nonsensational, straight-forward manner; and, the Appendixes provide a wealth of information in tabular format, including drug tables (names, strengths, formulations, pharmacokinetics, and dosing); advice on initiating and monitoring antipsychotic medications; common side effects and their management; and, special considerations for use during pregnancy and breastfeeding. "The Evidence-Based Guide to Antipsychotic Medications" is the first in a new series that strives to take evidence-based psychiatry from gold standard to standard practice. Scientifically up-to-date and rigorous, yet accessible and easy to understand, this volume stands alone as an indispensable resource on the topic.

As with Stahl's Essential Psychopharmacology and The Prescriber's Guide, Chronic Pain and Fibromyalgia is a full-colour title with a fun approach to theories. Stahl has been at the heart of many recent advances in the understanding of pain psychology, which has been reflected in the development of a new and wide variety of psychopharmologic and non-psychopharmologic pain medications. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Readers will find that the well-structured vocabulary combines with tables and algorithms to help build a vivid conception of current clinical strategies. The title is essential reading for pharmaceutical and mental health professionals, neurologists and pain management specialists. The Suggested Reading section at the end of the book is an invaluable tool for more in-depth learning on particular concepts.

Thoroughly updated for its sixth edition, "Handbook of Psychiatric Drug Therapy" is one of the most popular guides to the essential facts about all drugs used to treat anxiety, depression, bipolar disorders, psychotic disorders, substance abuse disorders, sleep disorders, dementia, and attention deficit disorder. Coverage of each drug includes mechanisms of action, indications, side effects, interactions, method of use, and caveats regarding special populations such as pregnant and elderly patients. The book gives specific prescribing recommendations - including dosage and duration of use - for individual drugs. Its tables provide at-a-glance information and a disease-specific table of contents directs readers quickly to relevant drug chapters.

As with Stahl's Essential Psychopharmacology, 3rd edition and The Prescriber's Guide, Attention Deficit Hyperactivity Disorder is a heavily illustrated title with a fun approach to theories. Stahl has been at the heart of significant advances in the treatment of ADHD in the past ten years, as new psychopharmacologic medications and cognitive and behavioral therapy techniques have been introduced into practice. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Novices to the series will find that the well-structured graphics and visual vocabulary can help build a vivid conception of complex pharmacologies. The complementary tables and algorithms provide clinical strategies and tips for drug dosaging, and the Suggested Reading section at the end of each book is an invaluable tool to guide the reader to more in-depth learning on particular concepts.

In response to rapid developments in psychopharmacology, this is a spin-off from Stephen M. Stahl's new, completely revised and updated version of his much-acclaimed Prescriber's Guide. It covers the most important drugs in use today for treating depression. In full color throughout, and with four or more pages for each antidepressant, Stephen M. Stahl distills his great expertise into a pragmatic formulary that gives all the information a prescriber needs to treat patients effectively. Each drug is covered in five categories: general therapeutics, dosing and use, side effects, special populations, and pearls. Target icons appear next to key categories for each drug so that the prescriber can go easily and instantly to the information needed. Several indices are included, listing drugs by name (generic and international) and use. In addition, Dr Stahl indicates which drugs have FDA approval and also gives the FDA Use-in-Pregnancy ratings.

In response to rapid developments in psychopharmacology, this is a spin-off from Stephen M. Stahl's new, completely revised and updated t

Its last edition hailed as "an essential volume for psychiatry residents as well as clinicians" (Journal of Psychiatric Practice), The American Psychiatric Publishing Textbook of Psychopharmacology is now updated to keep you abreast of the latest research and trends in the field. Covering both basic science and clinical practice, this new edition draws on the talents of 53 new contributors -- with the total increased from 139 to 158 -- to guarantee fresh, authoritative perspectives on advances in psychiatric drug therapy. Introductory chapters provide a theoretical grounding in clinical applications, with coverage ranging from neurotransmitters to clinical trial design. The "Classes of Psychiatric Treatment" section is a virtual pharmacopoeia, with chapters devoted to specific agents. It presents information by class of drug, and for each agent provides data on indications, side effects, interactions, and more -- including drugs likely to become available in the near future. Chapters in the "Clinical Psychobiology and Psychiatric Syndromes" section review the neurological underpinnings of specific disorders, providing a context for understanding psychopharmacological approaches to treatment. Coverage of those treatments encompasses state-of-the-art approaches to psychiatric disorders; specific patient populations, such as children and pregnant women; difficult-to-manage conditions like insomnia; and specific guidance on drug selection and prescription. Among the features of the fourth edition are the following * A new chapter on genomics and genetics covers basic methodologies and concepts to help you interpret the avalanche of data appearing in the human neuroscience literature.* Expanded chapters address newly approved agents, including the antidepressant desvenlafaxine, the antipsychotic paliperidone, and the anticonvulsant pregabalin.* A new chapter on the neurobiology of childhood disorders considers data relating to pervasive developmental disorders, psychoses, learning disorders, disruptive behavior disorder/ADHD, bipolar disorder, major depressive disorder, obsessive-compulsive disorder/Tourette's syndrome, PTSD, and pediatric anxiety disorders.* A new chapter on treatment of chronic pain syndromes discusses major classes of medications as they relate to pain management and covers prevalent disorders -- such as fibromyalgia and osteoarthritis -- in which this is a priority and for which evidence-based therapy is available.* A new, comprehensive review of ethical considerations in psychopharmacological treatment and research addresses such concerns as high-risk pharmacotherapy, long-acting medications, and off-label prescribing. Solidly established as an authoritative and comprehensive source, the new edition of this new edition of The American Psychiatric Publishing Textbook of Psychopharmacology is even more indispensable for clinicians and researchers alike.

L'obiettivo del volume è evidenziare il senso e lo scopo di una prescrizione farmacologica nel contesto di una specifica diagn

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

This is a book of psychiatry at its most practical level. It aims to answer the sorts of questions psychiatrists ask on a daily basis. What treatments are available for the condition that I think this patient has? What is the relative value of each of these treatments? Are there any other treatments that I should be considering if a first approach has failed? Is there any value in combinations of treatment? And, can I be sure that the evidence and recommendations I read are free from bias? The content is organised into three sections covering disease classification, the major treatment modalities and the application of these treatments to the wide range of psychiatric diagnoses. All professionals in mental health want to give the best treatments for their patients. This book provides clinicians with the knowledge and guidance to achieve this aim.

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.